Keywords
EmpagliflozinMedicineCanagliflozinHeart failureDrug classMyocardial infarctionDiabetes mellitusStroke (engine)DapagliflozinAdverse effectClinical trialInternal medicineFood and drug administrationPharmacologyCardiologyIntensive care medicineType 2 diabetesDrugEndocrinology
Affiliated Institutions
Related Publications
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
Despite current established therapy, heart failure (HF) remains a leading cause of hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to imp...
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
The benefits of SGLT2 inhibitors in heart failure may be mediated by the inhibition of sodium-hydrogen exchange rather than the effect on glucose reabsorption. This hypothesis h...
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
BACKGROUND In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through ...
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on...
A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
Background Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes wh...
Publication Info
- Year
- 2019
- Type
- article
- Volume
- 140
- Issue
- 6
- Pages
- 443-445
- Citations
- 61
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
61
OpenAlex
Cite This
Milton Packer
(2019).
Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
Circulation
, 140
(6)
, 443-445.
https://doi.org/10.1161/circulationaha.119.040909
Identifiers
- DOI
- 10.1161/circulationaha.119.040909